{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:26:55Z","timestamp":1793485615944,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40266-025-01183-8","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T13:14:22Z","timestamp":1740230062000},"page":"195-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials"],"prefix":"10.1007","volume":"42","author":[{"given":"Syeda Ayesha","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Mushahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Husain","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-2214","authenticated-orcid":false,"given":"Fakhar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabbia","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"1183_CR1","unstructured":"Federal Register. Guidance for industry on diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. [cited 2024 Apr 27]. Available from: https:\/\/www.federalregister.gov\/documents\/2008\/12\/19\/E8-30086\/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic."},{"key":"1183_CR2","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 [cited 2025 Jan 15];145. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001063.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"1183_CR3","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140.","journal-title":"Eur Heart J"},{"key":"1183_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102:990\u20139.","journal-title":"Kidney Int"},{"key":"1183_CR5","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 13. Older adults: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S195\u2013207.","DOI":"10.2337\/dc22-S013"},{"key":"1183_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.20517\/jca.2022.30","volume":"2","author":"D Tong","year":"2022","unstructured":"Tong D. SGLT2 inhibitors in patients with HFpEF: how old is too old? J Cardiovasc Aging. 2022;2:41.","journal-title":"J Cardiovasc Aging."},{"key":"1183_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106396","volume":"183","author":"ME Lunati","year":"2022","unstructured":"Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183: 106396.","journal-title":"Pharmacol Res"},{"key":"1183_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jgs.14028","volume":"64","author":"AJ Sinclair","year":"2016","unstructured":"Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64:543\u201352.","journal-title":"J Am Geriatr Soc"},{"key":"1183_CR9","doi-asserted-by":"crossref","unstructured":"Amioka M, Kinoshita H, Fuji Y, Nitta K, Yamane K, Shokawa T, et al. Long\u2010term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS\u2010HF study. ESC Heart Failure. 2025;12:447\u201355.","DOI":"10.1002\/ehf2.15088"},{"key":"1183_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care. 2020;43:468\u201375.","journal-title":"Diabetes Care"},{"key":"1183_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019;48:859\u201366.","journal-title":"Age Ageing"},{"key":"1183_CR12","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","volume":"4","author":"RE Pratley","year":"2023","unstructured":"Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4:e143\u201354.","journal-title":"Lancet Healthy Longev."},{"key":"1183_CR13","doi-asserted-by":"crossref","unstructured":"Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, et al. Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circ Heart Fail [Internet]. 2022 [cited 2025 Jan 15];15. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCHEARTFAILURE.122.010080.","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080"},{"key":"1183_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","volume":"141","author":"FA Martinez","year":"2020","unstructured":"Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141:100\u201311.","journal-title":"Circulation"},{"key":"1183_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2022.12.015","volume":"82","author":"TW Yi","year":"2023","unstructured":"Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, et al. Kidney and cardiovascular effects of canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial. Am J Kidney Dis. 2023;82:84-96.e1.","journal-title":"Am J Kidney Dis"},{"key":"1183_CR16","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2666-7568(23)00039-9","volume":"4","author":"S Bellary","year":"2023","unstructured":"Bellary S, Barnett AH. SGLT2 inhibitors in older adults: overcoming the age barrier. Lancet Healthy Longev. 2023;4:e127\u20138.","journal-title":"Lancet Healthy Longev."},{"key":"1183_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001279","volume":"8","author":"C Engler","year":"2020","unstructured":"Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012\u20132018. BMJ Open Diabetes Res Care. 2020;8: e001279.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1183_CR18","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1111\/dom.15193","volume":"25","author":"M Rigato","year":"2023","unstructured":"Rigato M, Fadini GP, Avogaro A. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25:2963\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1183_CR19","doi-asserted-by":"publisher","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","volume":"53","author":"R Aldafas","year":"2024","unstructured":"Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024;53:afad254.","journal-title":"Age Ageing"},{"key":"1183_CR20","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.","journal-title":"BMJ"},{"key":"1183_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"1183_CR22","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"1183_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557\u201360.","journal-title":"Br Med J"},{"key":"1183_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Butler J, Farmakis D, Ferreira JP, Gollop ND, et al. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of <scp>EMPEROR-Reduced<\/scp>. Eur J Heart Fail. 2022;24:2297\u2013304.","journal-title":"Eur J Heart Fail"},{"key":"1183_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","volume":"74","author":"F Triposkiadis","year":"2019","unstructured":"Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure. J Am Coll Cardiol. 2019;74:804\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"1183_CR26","doi-asserted-by":"crossref","unstructured":"Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its Assessment. GERONA. 2016;glw089.","DOI":"10.1093\/gerona\/glw089"},{"key":"1183_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/dom.14261","volume":"23","author":"SJ Han","year":"2021","unstructured":"Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab. 2021;23:682\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"1183_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, De Boer RA, Hernandez AF, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757\u201367.","journal-title":"Lancet"},{"key":"1183_CR29","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81:2377\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"1183_CR30","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson Jonathan R, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet"},{"key":"1183_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1183_CR32","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.eclinm.2021.101163","volume":"41","author":"N Staplin","year":"2021","unstructured":"Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. eClinicalMedicine. 2021;41:101163.","journal-title":"eClinicalMedicine."},{"key":"1183_CR33","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2337\/dc12-1801","volume":"35","author":"MS Kirkman","year":"2012","unstructured":"Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650\u201364.","journal-title":"Diabetes Care"},{"key":"1183_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:495\u2013502.","journal-title":"Eur J Prev Cardiol"},{"key":"1183_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","volume":"20","author":"M Rau","year":"2021","unstructured":"Rau M, Thiele K, Hartmann N-UK, Schuh A, Altiok E, M\u00f6llmann J, et al. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol. 2021;20:6.","journal-title":"Cardiovasc Diabetol"},{"key":"1183_CR36","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"1183_CR37","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2337\/dc17-0068","volume":"40","author":"N Marx","year":"2017","unstructured":"Marx N, McGuire DK, Perkovic V, Woerle H-J, Broedl UC, Von Eynatten M, et al. Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Diabetes Care. 2017;40:1144\u201351.","journal-title":"Diabetes Care"},{"key":"1183_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21:241.","journal-title":"BMC Med Res Methodol"},{"key":"1183_CR39","unstructured":"FDA Drug Safety Communication. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). [cited 2024 Apr 27]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin."},{"key":"1183_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijcard.2022.10.155","volume":"370","author":"A Galassi","year":"2023","unstructured":"Galassi A, Cara A, Magagnoli L, Faccioli FM, Cozzolino M. Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concerns. Int J Cardiol. 2023;370:321\u20132.","journal-title":"Int J Cardiol"},{"key":"1183_CR41","doi-asserted-by":"publisher","first-page":"afac201","DOI":"10.1093\/ageing\/afac201","volume":"51","author":"M Evans","year":"2022","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51:afac201.","journal-title":"Age Ageing"},{"key":"1183_CR42","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/bcp.14539","volume":"86","author":"RJ Van Marum","year":"2020","unstructured":"Van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol. 2020;86:2014\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"1183_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5:82.","journal-title":"Int J Heart Fail."},{"key":"1183_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148.","journal-title":"JAMA Cardiol."},{"key":"1183_CR45","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3390\/ijerph16162965","volume":"16","author":"A Tentolouris","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16:2965.","journal-title":"Int J Environ Res Public Health"},{"key":"1183_CR46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/ndt\/gfw092","volume":"31","author":"TM Esterhuizen","year":"2016","unstructured":"Esterhuizen TM, Thabane L. Con: meta-analysis: some key limitations and potential solutions. Nephrol Dial Transplant. 2016;31:882\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1183_CR47","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647\u2013g7647.","journal-title":"BMJ"},{"key":"1183_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4097\/kjae.2018.71.2.103","volume":"71","author":"E Ahn","year":"2018","unstructured":"Ahn E, Kang H. Introduction to systematic review and meta-analysis. Korean J Anesthesiol. 2018;71:103\u201312.","journal-title":"Korean J Anesthesiol"},{"key":"1183_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1507\/endocrj.EJ21-0616","volume":"69","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shao X, Liu Z. Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocr J. 2022;69:669\u201379.","journal-title":"Endocr J"},{"key":"1183_CR50","doi-asserted-by":"crossref","unstructured":"Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;h5651.","DOI":"10.1136\/bmj.h5651"},{"key":"1183_CR51","unstructured":"Shreffler J, Huecker MR. Type I and Type II errors and statistical power [Internet]. 2023 [cited 2024 Apr 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557530\/."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01183-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:18:11Z","timestamp":1741079891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01183-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01183-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"16 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.A. has received speaking fees from Bayer and AstraZeneca. S.A.S., H.M., A.S., S.H.F., F.L., R.S., A.J.N., and A.M.K.M. have no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conceptualization: S.A.S. Data curation: H.M. and S.H.F. Analysis: H.M., A.S. and S.H.F. Methodology: S.A.S., H.M. and A.S. Project administration: S.A.S. Supervision: S.A.S. Writing: S.A.S., H.M.,\u00a0A.S., S.H.F., and F.L. Reviewing and editing: A.M.K.M., D.A., A.J.N., and R.S.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}